Cargando…

Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China

Cancer patients are at a high risk of being infected with COVID-19 and have a poor prognosis after infection. Breast cancer is one of the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors an...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xin, Gao, Ping, Wang, Qiong, Wu, Hong-ge, Yan, Yun-li, Xia, Ying, Wang, Jian-ying, Lu, Fang, Pan, Hong, Yang, Yi, Liang, Fan, Zhao, Lei, Cheng, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595240/
https://www.ncbi.nlm.nih.gov/pubmed/34805207
http://dx.doi.org/10.3389/fmed.2021.741204
_version_ 1784600155939405824
author Peng, Xin
Gao, Ping
Wang, Qiong
Wu, Hong-ge
Yan, Yun-li
Xia, Ying
Wang, Jian-ying
Lu, Fang
Pan, Hong
Yang, Yi
Liang, Fan
Zhao, Lei
Cheng, Jing
author_facet Peng, Xin
Gao, Ping
Wang, Qiong
Wu, Hong-ge
Yan, Yun-li
Xia, Ying
Wang, Jian-ying
Lu, Fang
Pan, Hong
Yang, Yi
Liang, Fan
Zhao, Lei
Cheng, Jing
author_sort Peng, Xin
collection PubMed
description Cancer patients are at a high risk of being infected with COVID-19 and have a poor prognosis after infection. Breast cancer is one of the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors and analyzed their characteristics to provide evidence for boosting the vaccination rate. The researchers conducted a multicenter, cross-sectional study on 747 breast cancer survivors from six hospitals in Wuhan city between June 5, 2021, and June 12, 2021. The self-administrated questionnaires based on relevant studies were distributed. The researchers then compared differences in characteristics among vaccinated patients, hesitant patients, and non-vaccinated patients. Moreover, they performed univariable and multivariable logistic regression analyses to identify potential factors associated with vaccination hesitancy. The researchers assessed a total of 744 breast cancer survivors −94 cases in the vaccinated group, 103 in the planning group, 295 in the hesitancy group, and 252 in the refusal group. The vaccination rate was 12.63% (95% CI 10.25–15.02%) and 37.23% (95% CI 27.48–47.82%) patients reported adverse reactions. The vaccination hesitancy/refusal rate was 73.52% (95% CI 70.19–76.66%), which was independently associated with current endocrine or targeted therapy (odds ratio [OR] = 1.52, 95% CI 1.03–2.24), no notification from communities or units (OR = 2.46, 95% CI 1.69–3.59) and self-perceived feel (general vs. good, OR = 1.46, 95% CI 1.01–2.13; bad vs. good, OR = 4.75, 95% CI 1.85–12.16). In the hesitancy/refusal group, the primary reason was “I did not know who to ask whether I can get vaccinated” (46.07%), the person who would most influence decisions of patients was the doctor in charge of treatment (35.83%). Effective interaction between doctors and patients, simple and consistent practical guidelines on vaccination, and timely and positive information from authoritative media could combat misinformation and greatly reduce vaccine hesitancy among breast cancer survivors.
format Online
Article
Text
id pubmed-8595240
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85952402021-11-18 Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China Peng, Xin Gao, Ping Wang, Qiong Wu, Hong-ge Yan, Yun-li Xia, Ying Wang, Jian-ying Lu, Fang Pan, Hong Yang, Yi Liang, Fan Zhao, Lei Cheng, Jing Front Med (Lausanne) Medicine Cancer patients are at a high risk of being infected with COVID-19 and have a poor prognosis after infection. Breast cancer is one of the most common cancers. Since vaccination is an effective measure to prevent the spread of COVID-19, we studied the vaccination rate among breast cancer survivors and analyzed their characteristics to provide evidence for boosting the vaccination rate. The researchers conducted a multicenter, cross-sectional study on 747 breast cancer survivors from six hospitals in Wuhan city between June 5, 2021, and June 12, 2021. The self-administrated questionnaires based on relevant studies were distributed. The researchers then compared differences in characteristics among vaccinated patients, hesitant patients, and non-vaccinated patients. Moreover, they performed univariable and multivariable logistic regression analyses to identify potential factors associated with vaccination hesitancy. The researchers assessed a total of 744 breast cancer survivors −94 cases in the vaccinated group, 103 in the planning group, 295 in the hesitancy group, and 252 in the refusal group. The vaccination rate was 12.63% (95% CI 10.25–15.02%) and 37.23% (95% CI 27.48–47.82%) patients reported adverse reactions. The vaccination hesitancy/refusal rate was 73.52% (95% CI 70.19–76.66%), which was independently associated with current endocrine or targeted therapy (odds ratio [OR] = 1.52, 95% CI 1.03–2.24), no notification from communities or units (OR = 2.46, 95% CI 1.69–3.59) and self-perceived feel (general vs. good, OR = 1.46, 95% CI 1.01–2.13; bad vs. good, OR = 4.75, 95% CI 1.85–12.16). In the hesitancy/refusal group, the primary reason was “I did not know who to ask whether I can get vaccinated” (46.07%), the person who would most influence decisions of patients was the doctor in charge of treatment (35.83%). Effective interaction between doctors and patients, simple and consistent practical guidelines on vaccination, and timely and positive information from authoritative media could combat misinformation and greatly reduce vaccine hesitancy among breast cancer survivors. Frontiers Media S.A. 2021-11-03 /pmc/articles/PMC8595240/ /pubmed/34805207 http://dx.doi.org/10.3389/fmed.2021.741204 Text en Copyright © 2021 Peng, Gao, Wang, Wu, Yan, Xia, Wang, Lu, Pan, Yang, Liang, Zhao and Cheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Peng, Xin
Gao, Ping
Wang, Qiong
Wu, Hong-ge
Yan, Yun-li
Xia, Ying
Wang, Jian-ying
Lu, Fang
Pan, Hong
Yang, Yi
Liang, Fan
Zhao, Lei
Cheng, Jing
Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
title Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
title_full Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
title_fullStr Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
title_full_unstemmed Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
title_short Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China
title_sort prevalence and impact factors of covid-19 vaccination hesitancy among breast cancer survivors: a multicenter cross-sectional study in china
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595240/
https://www.ncbi.nlm.nih.gov/pubmed/34805207
http://dx.doi.org/10.3389/fmed.2021.741204
work_keys_str_mv AT pengxin prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT gaoping prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT wangqiong prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT wuhongge prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT yanyunli prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT xiaying prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT wangjianying prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT lufang prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT panhong prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT yangyi prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT liangfan prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT zhaolei prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina
AT chengjing prevalenceandimpactfactorsofcovid19vaccinationhesitancyamongbreastcancersurvivorsamulticentercrosssectionalstudyinchina